Literature DB >> 23595557

Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Pieter van Baal1, David Meltzer, Werner Brouwer.   

Abstract

Mesh：

Year:  2013        PMID： 23595557     DOI： 10.1007/s40273-013-0042-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

1.  Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.

Authors:  D Meltzer; M Johannesson
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

2.  Should the consumption of survivors be included as a cost in cost-utility analysis?

Authors:  John A Nyman
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

3.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

4.  Discounting and decision making in the economic evaluation of health-care technologies.

Authors:  Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J Culyer
Journal:  Health Econ       Date:  2010-05-12       Impact factor: 3.046

5.  In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.

Authors:  Jeffrey R J Richardson; Jan Abel Olsen
Journal:  Health Econ       Date:  2006-03       Impact factor: 3.046

6.  Future costs in cost effectiveness analysis.

Authors:  Robert H Lee
Journal:  J Health Econ       Date:  2007-12-07       Impact factor: 3.883

7.  Future costs in economic evaluation. A comment on Lee.

Authors:  Talitha L Feenstra; Pieter H M van Baal; Afshin Gandjour; Werner B F Brouwer
Journal:  J Health Econ       Date:  2008-07-25       Impact factor: 3.883

Review 8.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.

Authors:  Braden Manns; David Meltzer; Ken Taub; Cam Donaldson
Journal:  Health Econ       Date:  2003-11       Impact factor: 3.046

10.  Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Authors:  Daniel T Grima; Lisa M Bernard; Elizabeth S Dunn; Philip A McFarlane; David C Mendelssohn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981
View more
  5 in total

1.  The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra.

Authors:  Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

2.  Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran".

Authors:  Noga Gershon; Yakir Berchenko
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

Review 3.  Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic review.

Authors:  Thomas Grochtdreis; Christian Brettschneider; Annemarie Wegener; Birgit Watzke; Steffi Riedel-Heller; Martin Härter; Hans-Helmut König
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

4.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

Review 5.  Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.

Authors:  Matthew Franklin; James Lomas; Gerry Richardson
Journal:  Pharmacoeconomics       Date:  2020-07       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.